Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

MabThera Receives Positive Opinion In Europe For Treating Patients Whose Chronic Lymphocytic Leukaemia Returns
Roche announced that the European Union"s Committee on Human Medicinal Products (CHMP) has issued a positive recommendation for the use of MabThera (rituximab) in patients with relapsed or refractory chronic lymphocytic leukaemia (CLL). Physicians will soon be able to prescribe MabThera, the first monoclonal antibody therapy approved for previously untreated CLL, in combination with chemotherapy to patients who have been treated for the disease but whose cancer has returned or have not appropriately responded to therapy.

Lantheus Medical Imaging, Inc. Completes Enrollment Of CaRES Registry To Further Evaluate Definity(R) In Patients With Suboptimal Echocardiograms
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, announces that it has completed patient enrollment of CaRES (Contrast Echocardiography REgistry for Safety Surveillance), the first, multicenter Phase IV observational registry that evaluates the use of ultrasound imaging agents in routine clinical practice. The 1,060 patients who were enrolled at 15 sites in the U.S. were 18 years old or older and required DEFINITY® Vial for (Perflutren Lipid Microsphere) injectable suspension-enhanced echocardiography because of a previous suboptimal, unenhanced echocardiogram.
News of the day
Dramatic Increase In Social Isolation Cited By 2004 General Social Survey Is Disputed
A widely publicized analysis of social network size, which reported dramatically increasing social isolation when it was published in 2006, has sparked an academic debate in the August issue of the American Sociological Review (ASR), the flagship journal of the American Sociological Association.
Endocrinology

Daiichi Sankyo And MorphoSys Expand Collaboration With Two New Cancer-Related Antibody Programs

MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment, TecDAX) announced the start of a further two oncology-focused therapeutic antibody programs within its collaboration with DAIICHI SANKYO COMPANY, LIMITED (TSE: 4568, hereinafter Daiichi Sankyo). By exercising two options available under the parties" existing agreement, Daiichi Sankyo has selected two new target molecules against which MorphoSys will generate antibodies using its proprietary HuCAL technology. Daiichi Sankyo will carry out pre-clinical and clinical development and has worldwide marketing rights for all resulting products. MorphoSys receives exclusive license fees and stands to receive milestones and royalties for the therapeutic antibody programs, as per the terms of the companies" existing agreement. Further financial details were not disclosed. "The addition of these new oncology programs promises to strengthen still further our partnered antibody pipeline", commented Dr. Simon Moroney, CEO of MorphoSys. "We look forward to working with Daiichi Sankyo on the programs, and making progress towards our declared goal of establishing a broad therapeutic pipeline of HuCAL-based antibody drugs." The two companies have been engaged in joint application of MorphoSys"s advanced phage display and human antibody library technologies since March 2006. In March 2008, Daiichi Sankyo exercised its option to extend the contracting period until March 2011. Today, the collaboration encompasses four active therapeutic antibody programs. In May 2008, Daiichi Sankyo further strengthened its pipeline of novel targeted therapeutics in oncology by acquiring the German biotechnology company U3 Pharma AG. The cancer-related target molecules, which build the basis for the HuCAL-based programs, were part of U3 Pharma"s portfolio. Daiichi Sankyo and MorphoSys AG


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009